Cargando…
Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerat...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144132/ https://www.ncbi.nlm.nih.gov/pubmed/37108995 http://dx.doi.org/10.3390/jpm13040608 |
_version_ | 1785034029106462720 |
---|---|
author | Cieślikowski, Wojciech A. Milecki, Piotr Świerczewska, Monika Ida, Agnieszka Kasperczak, Michał Jankowiak, Agnieszka Nowicki, Michał Pantel, Klaus Alix-Panabières, Catherine Zabel, Maciej Antczak, Andrzej Budna-Tukan, Joanna |
author_facet | Cieślikowski, Wojciech A. Milecki, Piotr Świerczewska, Monika Ida, Agnieszka Kasperczak, Michał Jankowiak, Agnieszka Nowicki, Michał Pantel, Klaus Alix-Panabières, Catherine Zabel, Maciej Antczak, Andrzej Budna-Tukan, Joanna |
author_sort | Cieślikowski, Wojciech A. |
collection | PubMed |
description | The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch(®) system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56–74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch(®) system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter. |
format | Online Article Text |
id | pubmed-10144132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101441322023-04-29 Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer Cieślikowski, Wojciech A. Milecki, Piotr Świerczewska, Monika Ida, Agnieszka Kasperczak, Michał Jankowiak, Agnieszka Nowicki, Michał Pantel, Klaus Alix-Panabières, Catherine Zabel, Maciej Antczak, Andrzej Budna-Tukan, Joanna J Pers Med Article The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch(®) system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56–74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch(®) system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter. MDPI 2023-03-30 /pmc/articles/PMC10144132/ /pubmed/37108995 http://dx.doi.org/10.3390/jpm13040608 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cieślikowski, Wojciech A. Milecki, Piotr Świerczewska, Monika Ida, Agnieszka Kasperczak, Michał Jankowiak, Agnieszka Nowicki, Michał Pantel, Klaus Alix-Panabières, Catherine Zabel, Maciej Antczak, Andrzej Budna-Tukan, Joanna Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer |
title | Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer |
title_full | Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer |
title_fullStr | Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer |
title_full_unstemmed | Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer |
title_short | Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer |
title_sort | baseline ctc count as a predictor of long-term outcomes in high-risk prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144132/ https://www.ncbi.nlm.nih.gov/pubmed/37108995 http://dx.doi.org/10.3390/jpm13040608 |
work_keys_str_mv | AT cieslikowskiwojciecha baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT mileckipiotr baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT swierczewskamonika baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT idaagnieszka baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT kasperczakmichał baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT jankowiakagnieszka baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT nowickimichał baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT pantelklaus baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT alixpanabierescatherine baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT zabelmaciej baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT antczakandrzej baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer AT budnatukanjoanna baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer |